{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:46:19Z","timestamp":1794257179965,"version":"4.9.0"},"reference-count":48,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:00:00Z","timestamp":1643500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Polish Ministry of Education and Science.","award":["S16"],"award-info":[{"award-number":["S16"]}]},{"DOI":"10.13039\/501100014408","name":"National Institute of Geriatrics, Rheumatology and Rehabilitation","doi-asserted-by":"publisher","award":["S16"],"award-info":[{"award-number":["S16"]}],"id":[{"id":"10.13039\/501100014408","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objective: To investigate the associations of IL-18 serum levels with serum lipids, cardiovascular risk, and disease activity in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) with axial (axPsA) and peripheral (perPsA) joint involvement. Methods: 155 adult patients (PsA 61\/AS 94) were enrolled in the study. Standard disease activity indices, BASDAI, and ASDAS, were calculated for AS and PsA and DAPSA for PsA. Sera from peripheral blood samples were obtained after night fasting. Serum concentrations of cytokines (IL-18, IL-17) were measured by ELISA, while lipid profile with total cholesterol (TC), triglycerides (TG), low-density cholesterol-(LDL), high-density cholesterol (HDL), and C-reactive protein (CRP) concentrations were determined using routine procedures. The atherogenic index was calculated using the standard formula AI = TC\/HDL. Results: Patients with PsA and peripheral joint involvement (perPsA) had significantly higher IL-18 serum levels than axial PsA and AS patients (medians 160 vs. 116 vs. 80 pg\/mL). In patients with PsA and in the subgroup with PsA+ ischemic heart disease (IHD), IL-18 positively correlated with atherogenic index (AI) (rho = 0.46 and rho = 0.67, respectively) and TG serum concentrations (rho = 0.4 and rho = 0.675), while negatively with HDL levels (rho = \u22120.37 and rho = \u22120.608). In PsA + IHD subgroup IL-18 serum levels correlated positively also with disease activity (DAPSA) (rho = 0.613). Importantly, in patients with perPsA, characterized by the highest IL-18 serum levels, cardiovascular risk, and frequency of both hypertriglyceridemia and IHD, positive correlations between IL-18 and IL-17 (rho = 0.47, p = 0.002), TG (rho = 0.45 p = 0.01) levels and AI (rho = 0.63 p = 0.021) were found. Whereas linear regression models revealed that IL-17, TG concentrations and the tender joint count had an impact on IL-18 Conclusions: We confirmed that patients with perPsA are characterized by a more pronounced proinflammatory and proatherogenic cardiovascular risk profile than patients with axPsA and AS. Importantly our study indicates that in PsA, but not in AS, elevated serum concentration of IL-18 is associated with higher disease activity and proatherogenic lipid profile, leading to a higher cardiovascular risk. Thus, our results point out IL-18 as a critical contributor in these pathological processes and possible therapeutic targets.<\/jats:p>","DOI":"10.3390\/jcm11030766","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T01:46:08Z","timestamp":1643593568000},"page":"766","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Associations of IL-18 with Altered Cardiovascular Risk Profile in Psoriatic Arthritis and Ankylosing Spondylitis"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0814-4063","authenticated-orcid":false,"given":"Krzysztof","family":"Bonek","sequence":"first","affiliation":[{"name":"Department of Rheumatology, National Institute of Geriatrics, Rheumatology and Rehabilitation, 02-637 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9068-3885","authenticated-orcid":false,"given":"Ewa","family":"Kuca-Warnawin","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Immunology, National Institute of Geriatrics, Rheumatology and Rehabilitation, 02-637 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kornatka","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Immunology, National Institute of Geriatrics, Rheumatology and Rehabilitation, 02-637 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Zieli\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, National Institute of Geriatrics, Rheumatology and Rehabilitation, 02-637 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Wis\u0142owska","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, National Institute of Geriatrics, Rheumatology and Rehabilitation, 02-637 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Kontny","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Immunology, National Institute of Geriatrics, Rheumatology and Rehabilitation, 02-637 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5717-4472","authenticated-orcid":false,"given":"Piotr","family":"G\u0142uszko","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, National Institute of Geriatrics, Rheumatology and Rehabilitation, 02-637 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/annrheumdis-2014-206617","article-title":"Psoriasis, psoriatic arthritis and cardiovascular risk: Are we closer to a clinical recommendation?","volume":"74","author":"Kristensen","year":"2015","journal-title":"Ann. Rheum. Diseases."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.semarthrit.2016.05.011","article-title":"Active peripheral inflammation is associated with pro-atherogenic lipid profile in psoriatic arthritis","volume":"46","author":"Shrestha","year":"2016","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1136\/annrheumdis-2020-217595","article-title":"DAPSA, carotid plaque and cardiovascular events in psoriatic arthritis: A longitudinal study","volume":"79","author":"Lam","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3389\/fimmu.2018.00579","article-title":"Systemic inflammation and cardiovascular comorbidity in psoriasis patients: Causes and consequences","volume":"9","author":"Boehncke","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00403-017-1735-2","article-title":"Interleukin (IL)-18, cooperatively with IL-23, induces prominent inflammation and enhances psoriasis-like epidermal hyperplasia","volume":"309","author":"Shimoura","year":"2017","journal-title":"Arch. Dermatol. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-020-00215-6","article-title":"Obesity and psoriatic arthritis: A narrative review","volume":"7","author":"Kumthekar","year":"2020","journal-title":"Rheumatol. Ther."},{"key":"ref_8","first-page":"7353420","article-title":"Biomarkers of inflammation in obesity-psoriatic patients","volume":"2019","author":"Fabbrocini","year":"2019","journal-title":"Mediat. Inflamm."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Hu, S.C., and Lan, C.E. (2017). Psoriasis and cardiovascular comorbidities: Focusing on severe vascular events, cardiovascular risk factors and implications for treatment. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18102211"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1172\/JCI1333","article-title":"Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor","volume":"101","author":"Horwood","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.4049\/jimmunol.162.2.1096","article-title":"IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses","volume":"162","author":"Olee","year":"1999","journal-title":"J. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"713","DOI":"10.5114\/aoms.2011.24144","article-title":"Interleukin-18 expression and the response to treatment in patients with psoriasis","volume":"7","author":"Rasmy","year":"2011","journal-title":"Arch. Med Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3390\/nu5041218","article-title":"Dyslipidemia in obesity: Mechanisms and potential targets","volume":"5","author":"Klop","year":"2013","journal-title":"Nutrients"},{"key":"ref_14","first-page":"517","article-title":"Analysis of interleukin-17 and interleukin-18 levels in animal models of atherosclerosis","volume":"18","author":"Tang","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","article-title":"The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: Recent advances and controversies","volume":"78","author":"McGonagle","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3389\/fimmu.2013.00289","article-title":"Interleukin-18 and IL-18 binding protein","volume":"4","author":"Dinarello","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1136\/ard.2003.018481","article-title":"Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: Comparison with IL1 beta and tumour necrosis factor alpha","volume":"63","author":"Dai","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1006\/bbrc.2001.4380","article-title":"Interleukin-18 up-regulates osteoprotegerin expression in stromal\/osteoblastic cells","volume":"281","author":"Tsujimura","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"125705","DOI":"10.1155\/2013\/125705","article-title":"The role of inflammatory cytokines, the RANKL\/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis","volume":"2013","author":"Weitzmann","year":"2013","journal-title":"Scientifica"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Nozaki, Y., Ri, J., Sakai, K., Niki, K., Kinoshita, K., Funauchi, M., and Matsumura, I. (2019). Inhibition of the IL-18 receptor signaling pathway ameliorates disease in a murine model of rheumatoid arthritis. Cells, 9.","DOI":"10.3390\/cells9010011"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jbiosc.2021.02.007","article-title":"Exosomes from adipose derived mesenchymal stem cells alleviate diabetic osteoporosis in rats through suppressing NLRP3 inflammasome activation in osteoclasts","volume":"131","author":"Zhang","year":"2021","journal-title":"J. Biosci. Bioeng."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s12967-021-03071-2","article-title":"IL-18 binding protein suppresses IL-17-induced osteoclastogenesis and rectifies type 17 helper T cell\/regulatory T cell imbalance in rheumatoid arthritis","volume":"19","author":"Min","year":"2021","journal-title":"J. Transl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: Development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3758\/BF03206482","article-title":"AIC model selection using Akaike weights","volume":"11","author":"Wagenmakers","year":"2004","journal-title":"Psychon. Bull. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13075-020-2111-8","article-title":"A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations","volume":"22","author":"Sokolova","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e000749","DOI":"10.1136\/rmdopen-2018-000749","article-title":"Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies","volume":"4","author":"Braun","year":"2018","journal-title":"RMD Open"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e001568","DOI":"10.1136\/rmdopen-2021-001568","article-title":"Cardiovascular risk factors in gout, psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis: A cross-sectional survey of patients in Western Sweden","volume":"7","author":"Landgren","year":"2021","journal-title":"RMD Open"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13075-017-1315-z","article-title":"Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study","volume":"19","author":"Bengtsson","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_30","first-page":"1759720X211045263","article-title":"Distribution of comorbidities in spondyloarthritis with regard to the phenotype and psoriasis: Data from the ASAS-COMOSPA study","volume":"13","year":"2021","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1055\/s-0036-1584918","article-title":"Atherosclerosis in psoriatic arthritis: A multiparametric analysis using imaging technique and laboratory markers of inflammation and vascular function","volume":"25","author":"Garg","year":"2016","journal-title":"Int. J. Angiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 family of cytokines in psoriasis: IL-17A and beyond","volume":"9","author":"Brembilla","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Chehimi, M., Vidal, H., and Eljaafari, A. (2017). Pathogenic role of IL-17-producing immune cells in obesity, and related inflammatory diseases. J. Clin. Med., 6.","DOI":"10.3390\/jcm6070068"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00296-018-4183-1","article-title":"Comparison of the effects of exercise and anti-TNF treatment on cardiovascular health in rheumatoid arthritis: Results from two controlled trials","volume":"39","author":"Sandoo","year":"2019","journal-title":"Rheumatol. Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/art.22530","article-title":"Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors","volume":"57","author":"Llorca","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_36","first-page":"1310","article-title":"AB0733 Associations of serum osteoprotegerin and il-18 concentrations with cardiovascular risk in ankylosing spondylitis and psoriatic arthritis patients","volume":"76","author":"Kontny","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1136\/annrheumdis-2020-eular.4101","article-title":"AB0775 Peripheral joint inflammation is associated with more proatherogenic cardiovascular risk profile in patients with psoriatic arthritis","volume":"79","author":"Bonek","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1084\/jem.20090545","article-title":"Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis","volume":"206","author":"Taleb","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/eurheartj\/ehs399","article-title":"Interleukin-17 in atherosclerosis and cardiovascular disease: The good, the bad, and the unknown","volume":"34","author":"Liuzzo","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.it.2011.06.007","article-title":"T helper 17 cell heterogeneity and pathogenicity in autoimmune disease","volume":"32","author":"Ghoreschi","year":"2011","journal-title":"Trends Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/art.39332","article-title":"2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation collaborative initiative","volume":"68","author":"Ravelli","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.3389\/fimmu.2020.01840","article-title":"Human autoinflammatory diseases mediated by NLRP3-, pyrin-, NLRP1-, and NLRC4-inflammasome dysregulation updates on diagnosis, treatment, and the respective roles of IL-1 and IL-18","volume":"11","author":"Alehashemi","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","article-title":"Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome","volume":"131","author":"Weiss","year":"2018","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12969-020-00448-3","article-title":"Subclinical cardiovascular risk signs in adults with juvenile idiopathic arthritis in sustained remission","volume":"18","year":"2020","journal-title":"Pediatric Rheumatol. Online J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.3892\/mmr.2015.3753","article-title":"High and fluctuating glucose levels increase the expression and secretion of interleukin18 in mouse peritoneal macrophages","volume":"12","author":"Zhang","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1089\/sur.2013.269","article-title":"Endogenous interleukin 18 suppresses hyperglycemia and hyperinsulinemia during the acute phase of endotoxemia in mice","volume":"16","author":"Yamashita","year":"2015","journal-title":"Surg. Infect."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2337\/dc08-1710","article-title":"Interleukin-18 is a strong predictor of cardiovascular events in elderly men with the metabolic syndrome: Synergistic effect of inflammation and hyperglycemia","volume":"32","author":"Troseid","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1093\/eurheartj\/ehz542","article-title":"Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1beta inhibition with canakinumab: Further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis","volume":"41","author":"Ridker","year":"2020","journal-title":"Eur. Heart J."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/3\/766\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:11:42Z","timestamp":1760134302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/3\/766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,30]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["jcm11030766"],"URL":"https:\/\/doi.org\/10.3390\/jcm11030766","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,30]]}}}